Partner Headlines - BMY

  1. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  2. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  3. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  4. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  5. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  6. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  7. Bristol-Myers Drug Gets OK

    IBD
  8. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  9. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  10. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  11. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  12. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  13. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  14. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  15. Drugmaker AstraZeneca Returns To Growth

    IBD
  16. The Stocks Already in Correction Mode

    FoxBusiness
  17. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  18. Bristol-Myers surprises Street

    IBD
  19. Thursday Morning Earnings Reports

    Benzinga
  20. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  21. Earnings Scheduled For July 24, 2014

    Benzinga
  22. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  23. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  24. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  25. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  26. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  27. Bristol seeks cancer drug nod

    IBD
  28. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  29. Japan approves BMY regimen

    IBD
  30. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  31. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  32. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  33. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  34. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  35. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  36. Benzinga's Top Downgrades

    Benzinga
  37. Ex-Dividends For July 1, 2014

    Benzinga
  38. Pfizer and others get EU nods

    IBD
  39. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  40. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  41. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  42. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  43. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  44. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  45. BRISTOL-MYERS SQUIBB

    IBD
  46. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  47. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  48. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  49. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  50. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  51. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  52. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  53. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  54. Bristol, Merck Q1 sales soft

    IBD
  55. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  56. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  57. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  58. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  59. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone ...

    Benzinga
  60. Earnings Scheduled For April 29, 2014

    Benzinga
  61. Stocks To Watch For April 29, 2014

    Benzinga
  62. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  63. Earnings Expectations For The Week Of April 28: Big Oil, Big ...

    Benzinga
  64. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  65. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  66. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  67. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose ...

    Benzinga
  68. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  69. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  70. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  71. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  72. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  73. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  74. Gilead's HCV Challengers Near The Starting Gate

    IBD
  75. Gilead's HCV Challengers Near The Starting Gate

    IBD
  76. Abbott Capturing Incremental Market Share

    GuruFocus
  77. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  78. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  79. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  80. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  81. Bristol-Myers Squibb's

    IBD
  82. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  83. Market Wrap For February 24: Markets Showing Strength To Start ...

    Benzinga
  84. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  85. Actavis, Forest In $25 Bil Deal

    IBD
  86. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  87. Vanguard Health Care Fund's Top Five

    GuruFocus
  88. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on ...

    Benzinga
  89. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  90. Investors Brace for Bear Market

    FoxBusiness
  91. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  92. #PreMarket Primer: Monday, January 27: Markets Open The Week ...

    Benzinga
  93. Bristol-Myers Int'l Sales Soar

    IBD
  94. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  95. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  96. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  97. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  98. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  99. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  100. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down ...

    Benzinga
Trading Center